Aspreva Pharmaceuticals Corporation Halts CellCept Filing

NEW YORK - Shares of Aspreva Pharmaceuticals Corp. fell 6 percent in Monday morning trading after the company and partner Roche said they won't move forward with a regulatory submission for CellCept as a first-step therapy for lupus nephritis.